Principal Investigator
Namrata Chandhok
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231172
Clinical Trial Summary
A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): IMPACT Study
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Leukemia
Contact Information
Phone Number
305-243-2647